Literature DB >> 16905544

TcR and TcR-CD28 engagement of protein kinase B (PKB/AKT) and glycogen synthase kinase-3 (GSK-3) operates independently of guanine nucleotide exchange factor VAV-1.

Joanne E Wood1, Helga Schneider, Christopher E Rudd.   

Abstract

TcRzeta/CD3 and TcRzeta/CD3-CD28 signaling requires the guanine nucleotide exchange factor (GEF) Vav-1 as well as the activation of phosphatidylinositol 3-kinase, protein kinase B (PKB/AKT), and its inactivation of glycogen synthase kinase-3 (GSK-3). Whether these two pathways are connected or operate independently of each other in T-cells has been unclear. Here, we report that anti-CD3 and anti-CD3/CD28 can induce PKB and GSK-3alpha phosphorylation in the Vav-1(-/-) Jurkat cell line J. Vav.1 and in primary CD4-positive Vav-1(-/-) T-cells. Reduced GSK-3alpha phosphorylation was observed in Vav-1,2,3(-/-) T-cells together with a complete loss of FOXO1 phosphorylation. Furthermore, PKB and GSK-3 phosphorylation was unperturbed in the presence of GEF-inactive Vav-1 that inhibited interleukin-2 gene activation and a form of Src homology 2 domain-containing lymphocytic protein of 76-kDa (SLP-76) that is defective in binding to Vav-1. The pathway also was intact under conditions of c-Jun N-terminal kinase (JNK) inhibition and disruption of the actin cytoskeleton by cytochalasin D. Both events are down-stream targets of Vav-1. Overall, our findings indicate that the TcR and TcR-CD28 driven PKB-GSK-3 pathway can operate independently of Vav-1 in T-cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905544     DOI: 10.1074/jbc.M604878200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

Review 2.  Glycogen synthase kinase 3: a point of convergence for the host inflammatory response.

Authors:  Huizhi Wang; Jonathan Brown; Michael Martin
Journal:  Cytokine       Date:  2010-11-23       Impact factor: 3.861

3.  CD28 co-signaling in the adaptive immune response.

Authors:  Pavel Riha; Christopher E Rudd
Journal:  Self Nonself       Date:  2010-07-12

4.  Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways.

Authors:  Keunwook Lee; Prathyusha Gudapati; Srdjan Dragovic; Charles Spencer; Sebastian Joyce; Nigel Killeen; Mark A Magnuson; Mark Boothby
Journal:  Immunity       Date:  2010-06-25       Impact factor: 31.745

Review 5.  Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3).

Authors:  Eléonore Beurel; Suzanne M Michalek; Richard S Jope
Journal:  Trends Immunol       Date:  2009-10-14       Impact factor: 16.687

6.  Antigenic experience dictates functional role of glycogen synthase kinase-3 in human CD4+ T cell responses.

Authors:  Carlos A Garcia; Manjunatha R Benakanakere; Pascale Alard; Michelle M Kosiewicz; Denis F Kinane; Michael Martin
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

7.  CD28 and Grb-2, relative to Gads or Grap, preferentially co-operate with Vav1 in the activation of NFAT/AP-1 transcription.

Authors:  Helga Schneider; Christopher E Rudd
Journal:  Biochem Biophys Res Commun       Date:  2008-02-22       Impact factor: 3.575

Review 8.  Rho family GTPases and their regulators in lymphocytes.

Authors:  Victor L J Tybulewicz; Robert B Henderson
Journal:  Nat Rev Immunol       Date:  2009-08-21       Impact factor: 53.106

Review 9.  FOXO transcription factors throughout T cell biology.

Authors:  Stephen M Hedrick; Rodrigo Hess Michelini; Andrew L Doedens; Ananda W Goldrath; Erica L Stone
Journal:  Nat Rev Immunol       Date:  2012-09       Impact factor: 53.106

10.  Targeted knock-in mice expressing mutations of CD28 reveal an essential pathway for costimulation.

Authors:  Lindzy F Dodson; Jonathan S Boomer; Christine M Deppong; Dulari D Shah; Julia Sim; Traci L Bricker; John H Russell; Jonathan M Green
Journal:  Mol Cell Biol       Date:  2009-04-27       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.